BodycoteBOY
BOY logo
Fair Value
UK£8.87
Share price29 May
UK£9.052.0% overvalued intrinsic discount
Loading
1Y43.65%
7D-0.055%

US Aerospace And Defense Expansion Will Harness Industry 40 Trends

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
16 Mar 25
Updated
29 May 26
Views
85
Not Invested

Last Update 29 May 26

Fair value Increased 10%

BOY: Higher P/E Assumptions And M&A Optionality Will Shape Future Repricing

Narrative Update on Bodycote

The analyst price target for Bodycote has increased to £8.87 from £8.04, with analysts citing a combination of upward target revisions and valuation-driven rating changes across recent research.

Analyst Commentary

Recent research on Bodycote shows a mix of supportive and more cautious views, with changes in price targets and ratings largely framed around valuation and expectations for future execution.

Bullish Takeaways

  • Bullish analysts have lifted price targets into a range that runs up to 960 GBp, which signals confidence that the stock can justify a higher valuation if the company delivers on its plans.
  • The price target increase to 960 GBp suggests some analysts see room for upside in the current share price, assuming execution on operations and capital allocation stays on track.
  • The move by JPMorgan to adjust its target to 700 GBp while keeping a Neutral rating points to a view that Bodycote has scope to support a somewhat higher valuation even without a strongly positive stance on the stock.
  • Overall, the cluster of target revisions higher supports the idea that bullish analysts see the company as reasonably positioned for longer term growth, provided performance does not disappoint.

Bearish Takeaways

  • One bearish analyst lowered a price target by 15 GBp, which highlights some concern about how much investors should be willing to pay at current levels.
  • The downgrade to Sector Perform with an unchanged target of 775 GBp shows that some analysts now see the stock as fairly valued, with less room for valuation expansion without clear evidence of stronger execution.
  • The mix of Buy and Neutral or Sector Perform ratings suggests not all analysts are comfortable with the risk or timing of potential growth, so they prefer to wait for clearer proof points.
  • For investors, this split view means there is a live debate around whether the current share price already reflects much of the expected growth, leaving less margin for error if results or cash generation fall short of expectations.

What's in the News

  • Funds managed by Apollo Management X, L.P. and Apollo Global Management, Inc. proposed to acquire Bodycote plc for about £1.5b, offering 885 pence per share in cash plus a proposed final dividend of 16.1 pence per share for the 2025 financial year. The deal requires shareholder approval (Key Developments, M&A Transaction Announcements, May 22, 2026).
  • The Board of Directors authorized a share buyback plan, indicating that Bodycote is prepared to return capital to shareholders through repurchases alongside other uses of cash (Key Developments, Buyback Transaction Announcements, March 11, 2026).
  • Bodycote announced a share repurchase program of up to £80m, to be executed in two tranches of up to £40m each via Barclays Bank PLC. The program will run until the end of 2027 and is framed as part of balanced and disciplined capital allocation (Key Developments, Buyback Transaction Announcements, March 11, 2026).
  • Management indicated that Bodycote is actively looking for acquisitions, highlighting prior site sales and closures in France, a recent aerospace acquisition on the U.S. East Coast, and an intention to pursue more small and medium bolt-on deals aligned to its portfolio goals. The company has also hired a consultant focused on Aerospace & Defense (Key Developments, Seeking Acquisitions/Investments, 2025 full year results commentary).

Valuation Changes

  • Fair Value: the internal estimate has moved from £8.04 to £8.87 per share, a modest uplift in the assessed valuation level.
  • Discount Rate: the rate applied in the valuation has risen slightly from 9.08% to 9.32%, which generally reflects a somewhat higher required return.
  • Revenue Growth: the long term revenue growth input has been adjusted from 1.54% to 1.22%, a small reduction in the assumed growth pace.
  • Net Profit Margin: the margin assumption is broadly unchanged, moving fractionally from 12.12% to 12.08%.
  • Future P/E: the assumed forward P/E multiple has edged up from 18.20x to 20.11x, implying a slightly higher valuation multiple in the model.
7 viewsusers have viewed this narrative update

Key Takeaways

  • Capacity expansions, specialized investments, and focus on high-growth markets position Bodycote for accelerated revenue growth, market share gains, and a stronger business mix.
  • Continued innovation, optimization, and sustainability initiatives enhance pricing power, expand margins, and support long-term competitiveness in advanced material processing sectors.
  • Shrinking core markets, sector volatility, margin pressures, rising costs, and technological shifts threaten Bodycote's revenue stability and demand urgent adaptation to sustain growth.

Catalysts

About Bodycote
    Provides heat treatment and thermal processing services worldwide.
What are the underlying business or industry changes driving this perspective?
  • Major capacity expansions and upgrades in U.S. aerospace and defense sites are positioning Bodycote to capture higher demand as supply chain constraints ease and OEM order books grow, supporting future revenue acceleration and market share gains in these high-growth, high-margin sectors.
  • The company's targeted organic investments, focused M&A pipeline, and increased sales capability in specialized markets such as aerospace, defense, and medical devices diversify revenue sources and are expected to drive above-market growth while improving business mix, ultimately benefiting top-line growth and margin profile.
  • Momentum in Industry 4.0-related Specialist Technologies, such as HIP (Hot Isostatic Pressing) and vacuum treatments, combined with contract wins in defense and energy, position Bodycote at the forefront of increasing customer requirements for advanced material processing, translating to enhanced pricing power and improved net margins.
  • The expanded Optimise program, including site consolidations and divestitures of low-margin and structurally lower-growth assets, is set to deliver at least £15 million in recurring annual cost benefits by mid-2027, materially boosting EBIT margins and cash flow.
  • Bodycote's rollout of its Carbon Smart program-offering customers reduced carbon footprint heat treatment solutions-aligns with growing sustainability and electrification trends across automotive and industrial sectors, enabling the company to maintain pricing power, win new business, and protect or expand margins as decarbonization pressures mount.
Bodycote Earnings and Revenue Growth

Bodycote Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Bodycote's revenue will grow by 1.2% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 7.6% today to 12.1% in 3 years time.
  • Analysts expect earnings to reach £91.0 million (and earnings per share of £0.56) by about May 2029, up from £54.9 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 20.2x on those 2029 earnings, down from 25.4x today. This future PE is lower than the current PE for the GB Machinery industry at 26.0x.
  • Analysts expect the number of shares outstanding to decline by 2.67% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 9.32%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Bodycote's ongoing exposure to structurally weak and declining end markets, especially in Western Europe automotive and industrial segments, is leading to the closure or divestiture of up to 20% of its site portfolio and losing approximately £60 million in annual revenues; continued weakness in these sectors presents a risk of prolonged revenue stagnation or further contraction.
  • Over-reliance on cyclical sectors like aerospace and defense could result in earnings volatility; while these segments presently offer growth, any downturns or supply chain disruptions in these industries could quickly translate into significant drops in revenue and profitability.
  • Persistent pricing pressures and weak demand in several end markets, combined with the need to pass on surcharges or negotiate with large OEMs, could limit Bodycote's ability to maintain or expand margins over time, especially as peers in the space experience similar stresses.
  • Rising compliance, restructuring, and capital costs-including a 10% year-over-year increase in capex and substantial restructuring spend tied to site closures-may erode cash flow and net margins, particularly if the anticipated efficiency gains and cost savings from the Optimise program fail to fully materialize.
  • Increasing adoption of new technologies such as additive manufacturing, as well as heightened ESG and decarbonization requirements, could threaten demand for traditional heat treatment processes, forcing Bodycote to accelerate investment in next-generation solutions or risk long-term revenue decline and market share erosion.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of £8.87 for Bodycote based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £10.0, and the most bearish reporting a price target of just £7.25.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be £753.9 million, earnings will come to £91.0 million, and it would be trading on a PE ratio of 20.2x, assuming you use a discount rate of 9.3%.
  • Given the current share price of £8.17, the analyst price target of £8.87 is 7.9% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Bodycote?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

UK£8.87
vs UK£9.052.0% overvalued intrinsic discount
PastFuture0805m2015201820212024202620272029Revenue UK£753.9mEarnings UK£91.0m
1.2%
Revenue growth
12.1%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Bodycote

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Good value with adequate balance sheet.

Market capUK£1.5b
PB2.5x
Estimated Growth2.0%
Dividend Yield2.5%
Full analysis

CEO & management

James Fairbairn
CEO
2.6yrs
CEO Tenure

Provides heat treatment and thermal processing services worldwide.